Studies on ocular inflammation and development of a prostaglandin analogue for glaucoma treatment

Experimental Eye Research

Volumn 78, Issue 4, 2004, Pages 759-766

  Stjernschantz, Johan ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b Division of Pharmacology   (Sweden)

Author keywords

Eicosanoids; Glaucoma; Latanoprost; Neurogenic inflammation; Neuropeptides; Prostaglandins

Indexed keywords

12 HYDROXYICOSATETRAENOIC ACID; 15 HYDROPEROXYARACHIDONIC ACID; 17 PHENYL 18,19,20 TRINORPROSTAGLANDIN F2 ALPHA ISOPROPYL ACID; 5 HYDROXYICOSATETRAENOIC ACID; BIMATOPROST; CALCITONIN GENE RELATED PEPTIDE; CHOLECYSTOKININ A RECEPTOR ANTAGONIST; LATANOPROST; LEUKOTRIENE; LIPOXYGENASE; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN F2 ALPHA ISOPROPYL ESTER; PROSTAGLANDIN RECEPTOR AFFECTING AGENT; SUBSTANCE P; TRAVOPROST; UNCLASSIFIED DRUG;

AQUEOUS HUMOR; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG HYDROLYSIS; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG SYNTHESIS; EYE INFLAMMATION; EYE IRRITATION; GLAUCOMA; HERPES SIMPLEX KERATITIS; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; IRITIS; NEUROGENIC INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; RETINA MACULA CYSTOID EDEMA; REVIEW; VASOCONSTRICTION; VASODILATATION;

EID: 1342329790     PISSN: 00144835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exer.2003.11.016     Document Type: Article

References (94)

1. Albert D.M., Green W.R., Grossniklaus H.E., Zimbric M., Gangnon R.E., Fisher M.R., The Xalatan Pigment Study Group. Histopathological findings in iris specimens from patients with glaucoma treated with latanoprost. Inv. Ophthalmol. Vis. Sci. 41:2000;S509.
2. Alm A., Stjernschantz J., The Scandinavian Latanoprost Study Group. Effects on intraocular pressure and side effects of 0·005% latanoprost applied once daily, evening or morning. A comparison with timolol. Ophthalmology. 102:1995;1743-1752.
3. Alm A., Widengård I., Kjellgren D., Söderström M., Friström B., Heijl A., Stjernschantz J. Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. Br. J. Ophthalmol. 79:1995;12-16.
4. Alm A., Villumsen J. PhXA34, a new potent ocular hypotensive drug. A study on dose-response relationship and on aqueous humor dynamics in healthy volunteers. Arch. Ophthalmol. 109:1991;1564-1568.
5. Alm A., Villumsen J., Törnquist P., Mandahl A., Airaksinen J., Tuulonen A., Marsk A., Resul B., Stjernschantz J. Intraocular pressure-reducing effect of PhXA41 in patients with increased eye pressure. A one-month study. Ophthalmology. 100:1993;1312-1316.
6. Almegård B., Andersson S.E. Outflow facility in the monkey eye: effects of calcitonin gene-related peptide, cholecystokinin, galanin, substance P and capsaicin. Exp. Eye Res. 51:1990;685-689.
7. Almegård B., Stjernschantz J., Bill A. Cholecystokinin contracts isolated human and monkey iris sphincters; a study with CCK receptor antagonists. Eur. J. Pharmacol. 211:1992;183-187.
8. Ambache N. Properties of irin, a physiologic constituent of the rabbit iris. J. Physiol. (Lond). 135:1957;114-132.
9. Ambache N. Further studies on the preparation, purification and nature of irin. J. Physiol. (Lond). 146:1959;255-294.
10. 2α prostaglandins and related factors 21. Biochem. Pharmacol. 13:1964;281-283.
11. 2α-induced ocular hyperemia. Exp. Eye Res. 59:1994;401-408.
12. 2α-induced ocular surface hyperemia by sensory nerves in rabbits. Curr. Eye Res. 16:1998;886-890.
13. Basu S., Sjöquist B., Stjernschantz J., Resul B. Corneal permeability to and ocular metabolism of phenyl substituted prostaglandin esters in vitro. Prostaglandins Leukotrienes Essential Fatty Acids. 50:1994;161-168.
14. Bernard C. Lecons sur la physiologie et la pathologie du système nerveux, Paris. vol. II:1858;. pp. 96, 205f.
15. Bill A., Andersson S.E., Almegård B. Cholecystokinin causes contraction of the pupillary sphincter in monkeys but not in cats, rabbits, rats and guinea pigs: antagonism by lorglumide. Acta Physiol. Scand. 138:1990;479-485.
16. Bill A., Stjernschantz J., Mandahl A., Brodin E., Nilsson G. Substance P: release on trigeminal nerve stimulation, effects in the eye. Acta Physiol. Scand. 106:1979;371-373.
17. Bito L.Z. Prostaglandins, other eicosanoids, and their derivatives as potential antiglaucoma agents. Drance S.M., Neufeld A.H. Glaucoma; Applied Pharmacology and Medical Treatment. 1984;477-505 Grune and Stratton, Orlando, FL.
18. 2. Invest. Ophthalmol. Vis. Sci. 24:1983;376-380.
19. Butler J.M., Powell D., Unger W.G. Substance P levels in normal and sensorily denervated rabbit eyes. Exp. Eye Res. 30:1980;311-313.
20. 2α. Curr. Eye Res. 1:1981;205-209.
21. Camras C.B., The United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month, masked, multicenter trial in the United States. Ophthalmology. 103:1996;138-147.
22. 2α-induced ocular hypotension in monkeys. Arch. Ophthalmol. 105:1987;1112-1116.
23. Davies S.S., Ju W.-K., Neufeld A.H., Abran D., Chemtob S., Roberts II, L-Jackson. Hydrolysis of bimatoprost (Lumigan) to its free acid by ocular tissue in vitro. J. Ocul. Pharmacol. Ther. 19:2003;45-54.
24. Drago F., Marino A., La Manna C. α-Methyl-p-tyrosine inhibits latanoprost-induced melanogenesis in vitro. Exp. Eye Res. 68:1999;85-90.
25. Dutkiewicz R., Albert D.M., Levin L.A. Effects of latanoprost on tyrosinase activity and mitotic index of cultured melanoma lines. Exp. Eye Res. 70:2000;563-569.
26. Eakins K.E. Prostaglandin and non-prostaglandin breakdown of the blood-aqueous barrier. Exp. Eye Res. 25:1977;483-498.
27. 2α increases uveoscleral outflow in the cynomolgus monkey. Exp. Eye Res. 49:1989;389-402.
28. 2α in the human eye. Graefes Arch. Klin. Exp. Ophthalmol. 222:1985;139-141.
29. Grierson I., Cracknell K.P.B., Pfeiffer N. The iris after prostanoid treatment. Curr. Opin. Ophthalmol. 12:2001;112-118.
30. Grierson I., Pfeiffer N. The morphology of irides treated with latanoprost. Diestelhorst M. Prostaglandins in Ophthalmology. 1998;105-110 Kaden, Heidelberg.
31. Hellberg M.R., Sallee V.L., McLaughlin M.A., Sharif N.A., DeSantis L., Dean T.R., Zinke P.W. Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist. J. Ocul. Pharmacol. Ther. 17:2001;421-432.
32. Hotehama Y., Mishima H.K., Kitazawa Y., Masuda K. Ocular hypotensive effect of PhXA41 in patients with ocular hypertension or primary open angle glaucoma. Jpn. J. Ophthalmol. 37:1993;270-274.
33. 2α and latanoprost on cultured human iridial melanocytes. Exp. Eye Res. 70:2000;113-120.
34. Jampol L.M., Neufeld A.H., Sears M.L. Pathways for the response of the eye to injury. Invest. Ophthalmol. 14:1975;184-189.
35. Lindén C., Alm A. The effect on intraocular pressure of latanoprost once or four times daily. Br. J. Ophthalmol. 85:2001;1163-1166.
36. Lindén C., Nuija E., Alm A. Effects on IOP restoration and blood-aqueous barrier after long-term treatment with latanoprost in open angle glaucoma and ocular hypertension. Br. J. Ophthalmol. 81:1997;370-372.
37. Lindsey J.D., Kashiwagi K., Boyle D., Kashiwagi F., Firestein G.S., Weinreb R.N. Prostaglandins increase proMMP-1 and proMMP-3 secretion by human ciliary smooth muscle cells. Curr. Eye Res. 15:1996;869-875.
38. Lindsey J.D., Kashiwagi K., Kashiwagi F., Weinreb R.N. Prostaglandin action on ciliary smooth muscle extracellular matrix metabolism: implications for uveoscleral outflow. Surv. Ophthalmol. 41:1997;S53-S59.
39. 2α in human ciliary muscle cells. Invest. Ophthalmol. Vis. Sci. 35:1994;242-250.
40. Lindsey J.D., Weinreb R.N. Effects of prostaglandins on uveoscleral outflow. Alm A., Weinreb R.N. Uveoscleral Outflow. Biology and Cinical Aspects. 1998;41-55 Mosby-Wolfe.
41. Lindquist N.-G., Larsson B.S., Stjernschantz J. Increased pigmentation of iridial melanocytes in primates induced by a prostaglandin analogue. Exp. Eye Res. 68:1999;431-436.
42. Magendie F. De l'influence de la cinquiéme paire de nerfs sur la nutrition et les functions de l'oeil. J. Physiol. Exp. Pathol. 4:1824;176-200.
43. Nagasubramanian S., Sheth G.P., Hitchings R.A., Stjernschantz J. Intraocular pressure-reducing effect of PhXA41 in ocular hypertension: comparison of dose regimens. Ophthalmology. 100:1993;1305-1311.
44. Netland P.A., Landry T., Sullivan E.K., Andrew R., Silver L., Weiner A., Mallick S., Dickerson J., Bergamini M.V., Robertson S.M., Davis A.A., Travoprost Study Group. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am. J. Ophthalmol. 132:2001;472-484.
45. 2 on the disruption of the blood-aqueous barrier in the rabbit eye. Exp. Eye Res. 17:1973;445-448.
46. 2α-isopropyl ester in the cynomolgus monkey. Exp. Eye Res. 48:1989;707-716.
47. 2α-IE) on uveoscleral outflow. Bito L.Z., Stjernschantz J. The Ocular Effects of Prostaglandins and Other Eicosanoids. Progress in Clinical and Biological Research 312. 1989;429-436 Alan R. Liss, Inc, New York.
48. Noecker R.S., Dirks M.S., Choplin N.T., Bernstein P., Batoosingh A.L., Whitcup S.M., Bimatoprost/Latanoprost Study Group. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am. J. Ophthalmol. 135:2003;55-63.
49. Ocklind A. Effect of latanoprost on the extracellular matrix of the ciliary muscle: a study on cultured cells and tissue sections. Exp. Eye Res. 67:1998;179-191.
50. Oksala O. Effects of calcitonin gene-related peptide and substance P on regional blood flow in the cat eye. Exp. Eye Res. 47:1988;283-289.
51. Oksala O., Stjernschantz J. Effects of calcitonin gene-related peptide in the eye. A study in rabbits and cats. Invest. Ophthalmol. Vis. Sci. 29:1988;1006-1011.
52. Oksala O., Stjernschantz J. Increase in outflow facility of aqueous humour in cats induced by calcitonin gene-related peptide. Exp. Eye Res. 47:1988;787-790.
53. Parrish R.K., Palmberg P., Sheu W.P., XLT Study Group. A comparison of latanoprost, bimatoprost and travoprost in patients with elevated intraocular pressure: a 12-week, randomised, masked-evaluator, multicenter study. Am. J. Ophthalmol. 135:2003;688-703.
54. Perkins E.S. Influence of fifth cranial nerve on the intraocular pressure of the rabbit eye. Br. J. Ophthalmol. 41:1957;257-300.
55. Prota G., Vincensi M.R., Napolitano A., Selén G., Stjernschantz J. Latanoprost stimulated eumelanogenesis in iridial melanocytes of cynomolgus monkeys. Pigment Cell Res. 13:2000;147-150.
56. Resul B., Stjernschantz J., No K., Liljebris C., Selén G., Astin M., Karlsson M., Bito L.Z. Phenyl-substituted prostaglandins: potent and selective antiglaucoma agents. J. Med. Chem. 36:1993;243-248.
57. Resul B., Stjernschantz J., Selén G., Bito L.Z. Structure-activity relationships and receptor profiles of some ocular hypotensive prostanoids. Surv. Ophthalmol. 41:1997;S47-S52.
58. Sagara T., Gaton D.D., Lindsey J.D., Gabelt B.T., Kaufman P.L., Weinreb R.N. Topical prostaglandin F2alpha treatment reduces collagens type I, III and IV in the monkey uveoscleral outflow pathway. Arch. Ophthalmol. 117:1999;794-801.
59. Schumer R.A., Camras C.B., Mandahl A.K. Putative side-effects of prostaglandin analogs. Surv. Ophthalmol. 47:2002;S219-S230.
60. Selén G., Stjernschantz J., Resul B. Prostaglandin-induced iridial pigmentation in primates. Surv. Ophthalmol. 41:1997;S125-S128.
61. Sjöquist B., Johansson A., Stjernschantz J. Pharmacokinetics of latanoprost in the cynomolgus monkey. 3rd communication: tissue distribution after topical administration on the eye studied by whole body autoradiography. Arzneim.-Forsch./Drug Res. 49:1999;240-249.
62. Sjöquist B., Stjernschantz J. Ocular and systemic pharmacokinetics of latanoprost in humans. Surv. Ophthalmol. 47:2002;S6-S12.
63. Soloway M.R., Stjernschantz J., Sears M.L. The miotic effect of substance P on the isolated rabbit iris. Invest. Ophthalmol. Vis. Sci. 20:1981;47-52.
64. 2α on cat and rhesus monkey eyes. Invest. Ophthalmol. Vis. Sci. 22:1982;588-598.
65. Stjernschantz J. Autacoids and neuropeptides. Sears M.L. Pharmacology of the Eye. Handbook of Experimental Pharmacology 69. 1984;311-365 Springer, Berlin.
66. Stjernschantz J. Role of substance P in the acute irritative response of the rabbit eye, and effect of substance P antagonist analogs. Håkanson R., Sundler F. Tachykinin Antagonists. 1985;119-131 Elsevier, Amsterdam.
67. 2α-isopropyl ester to latanoprost: a review of the development of Xalatan. The Proctor Lecture. Invest. Ophthalmol. Vis. Sci. 42:2001;1134-1145.
68. Stjernschantz J.W., Albert D.M., Hu D.-N., Drago F., Wistrand P.J. Mechanism and clinical significance of prostaglandin-induced iris pigmentation. Surv. Ophthalmol. 47:2002;S162-S175.
69. Stjernschantz J., Geijer C., Bill A. Electrical stimulation of the fifth cranial nerve in rabbits: Effects on ocular blood flow, extravascular albumin content and intraocular pressure. Exp. Eye Res. 28:1979;229-238.
70. Stjernschantz J., Ocklind A., Wentzel P., Lake S., Hu D.-N. Latanoprost-induced increase of tyrosinase transcription in iridial melanocytes. Acta Ophthalmol. Scand. 78:2000;618-622.
71. Stjernschantz J., Resul B. Phenyl substituted prostaglandin analogs for glaucoma treatment. Drugs Future. 17:1992;691-704.
72. Stjernschantz J., Sears M.L., Mishima H. Role of substance P in the antidromic vasodilation, neurogenic plasma extravasation and disruption of the blood-aqueous barrier in the rabbit eye. Naunyn Schmiedeberg's Arch. Pharmacol. 321:1982;329-335.
73. Stjernschantz J., Sears M., Stjernschantz L. Intraocular effects of substance P in the rabbit. Invest. Ophthalmol. Vis. Sci. 20:1981;53-60.
74. Stjernschantz J., Selén G., Astin M., Resul B. Microvascular effects of selective prostaglandin analogues in the eye with special reference to latanoprost and glaucoma treatment. Progr. Retinal Eye Res. 19:2000;459-496.
75. Stjernschantz J., Selén G., Ocklind A., Resul B. Effects of latanoprost and related prostaglandin analogues. Alm A., Weinreb R.N. Effects of Latanoprost and Related Prostaglandin Analogues. 1998;57-72 Mosby-Wolfe.
76. 2α analogue. Samuelsson B. Advances in Prostaglandin, Thromboxane and Leukotriene Research. vol. 23:1995;513-518 Raven Press, New York.
77. Stjernschantz J., Sherk T., Borgeat P., Sears M.L. Intraocular effects of lipoxygenase pathway products in arachidonic acid metabolism. Acta Ophthalmol. Scand. 62:1984;104-111.
78. 4 in the cat. Prostaglandins. 27:1984;5-15.
79. Stjernschantz J., von Dickhoff K., Oksala O., Seppä H. A study of the mechanism of ocular irritation following YAG laser capsulotomy in rabbits. Exp. Eye Res. 43:1986;641-651.
80. 2α analog, on aqueous humor dynamics in human eyes. Ophthalmology. 100:1993;1297-1304.
81. Unger W.G. Mediation of the ocular response to injury and irritation: peptides versus prostaglandins. Bito L.Z., Stjernschantz J. The Ocular Effects of Prostaglandins and other Eicosanoids. Progress in Clinical and Biological Research 312. 1989;293-328 Alan R. Liss, Inc, New York.
82. Unger W.G., Terenghi G., Ghatei M.A., Butler J.M., Polak J.M., Bloom S.R. Calcitonin gene-related polypeptide as a mediator of the neurogenic ocular injury response. J. Ocul. Pharmacol. 1:1985;185-195.
83. Unger W.G., Tighe J. The response of the isolated iris sphincter muscle of various mammalian species to substance P. Exp. Eye Res. 39:1984;677-684.
84. Wahlestedt C., Beding B., Ekman R., Oksala O., Stjernschantz J., Håkanson R. Calcitonin gene-related peptide in the eye: release by sensory nerve stimulation and effects associated with neurogenic inflammation. Regul. Pept. 16:1986;107-115.
85. Watson P., Stjernschantz J., The Latanoprost Study Group. Six-month, randomised, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology. 103:1996;126-137.
86. Weinreb R.N., Kashiwagi K., Kashiwagi F., Tsukahara S., Lindsey J.D. Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. Invest. Ophthalmol. Vis. Sci. 38:1997;2772-2780.
87. Weinreb R.N., Lindsey J.D. Metalloproteinase gene transcription in human ciliary muscle cells with latanoprost. Invest. Ophthalmol. Vis. Sci. 43:2002;716-722.
88. Wentzel P., Bergh K., Wallin Ö., Niemelä P., Stjernschantz J. Transcription of prostanoid receptor genes and cyclooxygenase enzyme genes in cultivated human iridial melanocytes from eyes of different colour. Pigment Cell Res. 16:2003;43-49.
89. 2α-isopropyl ester eye drops: effects in normal human eyes. Br. J. Ophthalmol. 73:1989;419-426.
90. 2α esters. A double masked cross-over study on normotensive eyes. Acta Ophthalmol. Scand. 68:1990;341-343.
91. 2α analogue: effect on intraocular pressure in patients with ocular hypertension. Br. J. Ophthalmol. 76:1992;214-217.
92. Wistrand P.J., Stjernschantz J., Olsson K. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Surv. Ophthalmol. 41:1997;S129-S138.
93. Zahn G.-L., Toris C.B., Camras C.B., Wang Y.L., Bito L.Z. Prostaglandin-induced iris color darkening. An experimental model. Arch. Ophthalmol. 116:1998;1065-1068.
94. 2α analogue, after topical application in normal and ocular hypertensive human eyes. Arch. Ophthalmol. 111:1993;1351-1358.